News filter
No results found.
Manufacturing More Tomorrows™
Partner with us and benefit from a team with technical expertise and a passion for purpose. As a true partner, strategically minded and dedicated to your lasting legacy, we provide customized solutions tailored to your precise requirements. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.
Let’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.
You may also be interested in...
Explore our library of resources to discover valuable insights on the latest trends in drug delivery.
Built for better tomorrows: How Bridgeton delivers for patients
Kindeva’s Bridgeton facility offers a purpose-built solution for the complex and evolving landscape of injectable drugs. The facility was specifically designed to address challenges in sterile injectable manufacturing, such as the siloed approaches that often separate core functions like formulation and fill finish. By co-locating these functions and operating within integrated systems, the Bridgeton model […]
Learn More
Building confidence into complex drug-device programs with early analytical expertise
Drug-device programs are under pressure to do more, with tighter timelines, deeper scrutiny and increasing complexity. As teams move from concept through clinical and commercial phases, one challenge remains constant: ensuring products behave as intended, consistently and safely. That challenge gets more complicated as formulation, device mechanics, packaging and regulatory expectations converge. Whether developing an […]
Learn More
What makes Bridgeton the perfect partner for your next sterile fill finish project?
The pharmaceutical sector is experiencing a significant increase in the demand for advanced biologics, biosimilar therapies and other sterile injectables. As a result, the global sterile injectables market is projected to grow from $632 billion in 2025 to $1.078 trillion by 2032, with a compound annual growth rate of 7.9% [1]. In response to this […]
Learn More
From vial to value: How GLP-1s are redefining injectable care for chronic conditions
The market for glucagon-like peptide-1 (GLP-1) therapies is growing rapidly, with a projected value of $186.6 billion by 2032. Originally developed for diabetes, these therapies are now widely used for obesity treatment, which has created a need for convenient and scalable delivery systems. This growth is reshaping the industry, creating new demands on manufacturing capacity […]
Learn More
The Kindeva Advantage: Setting the Gold Standard for Elemental Impurities Testing
In this blog, Jen Roark, Scientific Director of Injectables at Kindeva, explores the challenges of controlling elemental impurities in drug products. She breaks down the risks and regulatory guidelines outlined in USP <232> and ICH Q3D, then takes a deep dive into the findings of a recent PQRI interlaboratory study that highlights the complexities of […]
Learn More
A bridge to the future: Our world-class Bridgeton facility
Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging. A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, […]
Learn More
Mastering USP 661.1 and 661.2: Kindeva Drug Delivery Simplifies Your Path to Compliance
Understanding the evolution of USP <661.1> and <661.2> In this blog, Jen Roark, Scientific Director of Injectables at Kindeva, breaks down the critical shift in pharmaceutical packaging standards ahead of the fast-approaching December 1, 2025, implementation deadline. She covers the history of USP <661.1> and <661.2>, the move to a risk-based framework, specific testing requirements […]
Learn More
The impact of inlet design on HFA-152a pMDI drug delivery
When assessing aerodynamic particle size distribution (APSD) using the Next Generation Impactor (NGI), throat model selection can significantly influence drug deposition outcomes. Accurate deposition data is essential for optimising pMDI design and ensuring consistent, effective drug delivery to patients. Recent research by our pulmonary/pMDI experts—Aaron Taylor, Chad Haraldson, and Stephen Stein at Kindeva—explores how United […]
Learn More
Evaluating extractables in low-GWP pMDI formulations
As the pharmaceutical industry advances toward low global warming potential (GWP) propellants like HFA152a and HFO1234ze(E), understanding material compatibility becomes critical, especially when it comes to leachables from common device components. In a recent evaluation, a group of pulmonary experts at Kindeva assessed the extractable levels associated with various polybutylene terephthalate (PBT) suppliers in pressurized […]
Learn More